Olmesartan Medoxomil in Hypertension and Renal Impairment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00151827 |
Recruitment Status :
Completed
First Posted : September 9, 2005
Last Update Posted : October 14, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Essential Hypertension Renal Impairment | Drug: Olmesartan medoxomil Drug: Losartan Drug: Furosemide oral tablets | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 393 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment |
Study Start Date : | August 2003 |
Actual Primary Completion Date : | July 2005 |
Actual Study Completion Date : | July 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: Olmesartan medoxomil
Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
|
Drug: Olmesartan medoxomil
Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water. Drug: Furosemide oral tablets If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator |
Experimental: Losartan
Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
|
Drug: Losartan
Medications are taken once daily before breakfast with water. Drug: Furosemide oral tablets If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator |
- Change in mean sitting diastolic blood pressure (dBP), assessed by conventional blood pressure measurements after 12 weeks of treatment [ Time Frame: Baseline to 12 weeks ]
- Change in mean sitting diastolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment; [ Time Frame: Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks ]
- Change in mean sitting systolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment; [ Time Frame: Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks ]
- Response to treatment after 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks of treatment; [ Time Frame: Baseline to 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks ]Response to treatment = mean sitting diastolic blood pressure less than or equal to 90 mmHg or reduction greater than or equal to 10 mmHg
- Changes in creatinine clearance after 12 and 52 weeks of treatment, changes in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment; [ Time Frame: Baseline to 12 and 52 weeks ]
- Changes in serum creatinine after 12 and 52 weeks of treatment [ Time Frame: Baseline to 12 and 52 weeks ]
- Rate of patients per dose level after 12 and 52 weeks of treatment [ Time Frame: Baseline to 12 and 52 weeks ]
- Change in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment [ Time Frame: Baseline to 4, 12, 24, 36 and 52 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mean sitting BP prior to randomization of 140-180/90-109 mmHg;
- Renal impairment prior to randomization of mild (50 ≤ CLcr ≥ 80 mL/min) to moderate (30 ≤ CLcr ≥50 mL/min) severity
Exclusion Criteria:
- Malignant hypertension or sitting BP greater than 180/109 mmHg;
- Severe heart failure, severe renal disease;
- Recent history of myocardial infarction, stroke or transient ischemic attack;
- History, clinical or current evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial;
- Hypersensitivity or contraindications to ARBs or ACE inhibitors or any cross allergy;
- Treatment with dis-allowed medication;
- Pregnant or breastfeeding females or females of childbearing potential without adequate contraception;
- History of drug and/or alcohol abuse

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00151827
Germany | |
Darmstadt, Germany |
Principal Investigator: | P. U. Witte, MD, PhD | IMFORM GmbH, Darmstadt, Germany |
ClinicalTrials.gov Identifier: | NCT00151827 |
Other Study ID Numbers: |
SE-866/43 |
First Posted: | September 9, 2005 Key Record Dates |
Last Update Posted: | October 14, 2010 |
Last Verified: | October 2010 |
Renal Insufficiency Hypertension Essential Hypertension Vascular Diseases Cardiovascular Diseases Kidney Diseases Urologic Diseases Losartan Olmesartan Olmesartan Medoxomil Furosemide |
Anti-Arrhythmia Agents Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Diuretics Natriuretic Agents Physiological Effects of Drugs Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators |